Androcur the patient will now have to sign a form informing him of the risks of developing a tumor - Europe 1
Androcur, this drug indicated in particular against hyperpilosity, can multiply up to twenty the risk of developing a non -cancerous brain tumor. From July 1, any patient starting treatment must be informed of the risk and sign an annual information certificate.
Dès le 1er juillet, tout patient débutant un traitement avec Androcur ou ses génériques devra être informé du risque de tumeur lié à ces médicaments et bénéficier d’un examen d’imagerie cérébrale, selon l’Agence du médicament. « Cette information concerne principalement les femmes, l’acétate de cyprotérone, principe actif de ces médicaments, étant minoritairement prescrit aux hommes, notamment pour le cancer de prostate et les déviances sexuelles (castration chimique pour pédophilie et/ou viols à répétition) », explique le Dr Jean-Michel Race, endocrinologue, de l’ANSM.
An information sheet on the risk of meningioma (most often benign tumor) of these drugs must now be given by prescribing doctors to their patients. The latter will only be able to obtain these drugs in pharmacy on the compulsory presentation of an annual information certificate that they have signed as well as the prescribing doctor, from July 1 for new treatments and January 1, 2020 for renewals.
Find other articles from Amavea here
